NCT05980026View on ClinicalTrials.gov

Omega-3 Fatty Acids Supplementation Improves Early-stage Diabetic Nephropathy and Subclinical Atherosclerosis in Pediatric Patients With Type 1 Diabetes

NACompletedINTERVENTIONAL
Enrollment

70

Participants

Timeline

Start Date

January 10, 2022

Primary Completion Date

December 17, 2022

Study Completion Date

January 14, 2023

Conditions
Diabetes Mellitus, Type 1
Interventions
DRUG

oral omega-3 fatty acids supplementation

oral omega-3 fatty acids supplementation

DIETARY_SUPPLEMENT

Placebo

Patients in placebo group received placebo that were similar in appearance to omega 3 fatty acids and the administered dose was as the same schedule as omega 3 fatty acids.

Trial Locations (1)

11361

Nancy Elbarbary, Cairo

All Listed Sponsors
lead

Ain Shams University

OTHER

NCT05980026 - Omega-3 Fatty Acids Supplementation Improves Early-stage Diabetic Nephropathy and Subclinical Atherosclerosis in Pediatric Patients With Type 1 Diabetes | Biotech Hunter | Biotech Hunter